FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL
0.0.07.0.1.00.0.0

OMB Number: 3235-0287 Estimated average burden

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* BIOTIME INC					2. Issuer Name and Ticker or Trading Symbol Asterias Biotherapeutics, Inc. [AST]									Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below)				
(Last) (First) (Middle) 1010 ATLANTIC AVENUE, SUITE 102					3. Date of Earliest Transaction (Month/Day/Year) 02/29/2016													
(Street)	DA C	CA	94501		4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(9	State)	(Zip)															
		T	able I - Non-D	eriva	tive S	ecu	ırities Ad	quired	, Dis	posed (of, or Be	enefi	icially (Owned				
Date			Fransaction te onth/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Yea		Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4				5. Amount Securities Beneficiall Owned Fol Reported	Fori		Direct II Indirect E tr. 4) C	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) (D)	or	Price	Transactio (Instr. 3 an				(Instr. 4)
Series A Common Stock 02/29)2/29/2	29/2016			J ⁽¹⁾		75,7	71 I)	(1)	21,747,569		D		
			Table II - De (e.				ities Acq warrants							wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		Derivative		Expiration	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title		ount or nber of res		(Instr. 4)	ion(s)		
Warrants to purchase Series A Common	\$5	02/29/2016		J ⁽¹⁾			3,150,000	10/01/20	13	09/30/2016	Series A Common Stock	3,1	50,000	(1)	0		D	

Explanation of Responses:

1. The Reporting Person transferred to the Issuer 75,771 shares Series A Common Stock of the Issuer and warrants to purchase 3,150,000 shares of Series A Common Stock of the Issuer in connection with a (a) the cross-licensing and sublicensing of certain patent rights and technology between the Issuer, the Reporting Person and another subsidiary of the Reporting Person, and (b) the transfer of shares of capital stock of certain subsidiaries of the Reporting Person from the Issuer to the Reporting Person. The shares of Series A Common Stock were valued at \$3.07 per share, and the warrants were valued at \$2,906,883, by the Reporting Person and the Issuer for purposes of the transaction.

Remarks:

/s/ Russell Skibsted, Chief Financial Officer 03/02/2016

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.